$REE

REE Automotive Announces Receipt of Nasdaq Delisting Notice

REE Automotive (Nasdaq: REE) said Nasdaq notified it of a delisting determination after the company failed to regain compliance with Nasdaq’s $1.00 minimum bid price rule (Rule 5550(a)(2)) during an additional 180-day period ending June 29, 2026. Trading of its Class A ordinary shares will be suspended July 7, 2026, and Nasdaq will file Form 25-NSE.

Original reporting
Published Jul 3, 2026, 7:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 3, 2026, 7:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
REE Automotive Announces Receipt of Nasdaq Delisting Notice — source image
Decision brief

The 30-second read

$REEBearishHigh
01

Why it matters

Nasdaq’s delisting determination means REE’s shares will be suspended on July 7, 2026, and Nasdaq will file Form 25-NSE to remove the securities from listing/registration.

02

Market read

This is a direct, time-bound listing event that can materially change trading liquidity, spreads, and risk premia for REE.

03

What to watch

The article doesn’t quantify expected OTC liquidity, potential reverse-split plans, or any parallel financing/strategic actions that could offset delisting risk.

Relevance 9/10Novelty 9/10Timing: ahead of the July 7, 2026 Nasdaq trading suspension

Background

REE previously failed Nasdaq’s $1.00 minimum bid price requirement for 30 consecutive business days, received an initial 180-day period, then an additional 180-day extension.

Company-level read

Ticker impact

$REEBearishHigh confidence
Context

REE received a Nasdaq delisting determination and its Class A ordinary shares will be suspended from trading on July 7, 2026.

Expected impact

Near-term downside pressure is likely into the July 7 suspension, with elevated volatility as liquidity and listing risk worsen.

Evidence & confidence

The article discloses a concrete exchange action (delisting determination, suspension date, and intent not to request a hearing), which typically drives immediate risk repricing.

Market effects

Signals heightened listing-risk sensitivity for small-cap/early-stage automotive tech names reliant on maintaining minimum bid price compliance.

Primarily impacts US-listed Israeli tech equities; may spill into sentiment for similar cross-listed microcaps.

Limited broader global impact, but reinforces exchange compliance as a key risk factor for international issuers on Nasdaq.

Counterpoint

Some delisted names can continue trading on other venues (e.g., OTC) and may see stabilization if investors expect a path to regain compliance or restructure.

Key entities

  • REE Automotive Ltd.

    Nasdaq-listed automotive technology company receiving the delisting determination and scheduling a July 7, 2026 suspension.

  • Nasdaq Stock Market LLC

    Exchange authority issuing the delisting determination under Listing Rule 5550(a)(2).

Related articles

$CEROHighAI 8/10

Delisting of Securities from The Nasdaq Stock Market

Nasdaq said it will delist multiple issuers’ securities from the Nasdaq Stock Market, including CERo Therapeutics Holdings, Bowen Acquisition Corp, Graphjet Technology, Blue Hat Interactive Entertainment Technology, X3 Holdings Co, Captivision Inc, Actelis Networks, American Rebel Holdings, Reviva Pharmaceuticals, Alchemy Investments Acquisition Corp 1, Bitcoin Depot, Inotiv, GoHealth, Functional Brands, Sleep Number, Smart Digital Group, and REE Automotive. Most were suspended in 2025-2026 and

$METAMedAI 9/10

An $18bn settlement – and Zuckerberg barely blinked. The tech titans must be stripped of their power, and soon | Jonathan Freedland

Meta agreed to an $18bn settlement with 29 US states over claims its platforms harmed children. Despite the large sum, Meta's stock rose, as the payment is manageable over 10 years. The settlement includes usage restrictions for young users but no admission of liability. Critics argue the deal does not address core issues like the recommendation algorithm or global impact.

$GILDHighAI 9/10

FDA approves smallest single-pill HIV regimen, Bixlenvo

The FDA approved Gilead Sciences' Bixlenvo, a single-pill HIV therapy combining bictegravir and lenacapavir. It is the smallest daily regimen for virologically suppressed adults on complex treatments. Gilead claims it will benefit aging patients and those with resistance or tolerability issues. Approval was based on ARTISTRY-1 and ARTISTRY-2 trial data.

$MRNAMedAI 8/10

What you need to know about updated COVID vaccines following FDA approval

FDA approved updated COVID-19 vaccines from Moderna, Pfizer, and Sanofi targeting the XFG strain, which accounts for 40% of U.S. cases. Moderna's vaccine is approved for ages 6 months to 64 with conditions and all adults 65+. Pfizer's is for ages 5 to 64 with conditions and all adults 65+. Availability is expected in pharmacies, hospitals, and clinics. Insurance coverage is uncertain, but most plans may cover it. Experts emphasize vaccination to prevent severe disease, especially for high-risk g

$DELLMedAI 8/10

Dell Failed to Defeat Challenge to $11 Billion Navy Contract

Dell Federal Systems LP lost a legal bid to dismiss a challenge to its $11.4 billion US Navy contract. The US Court of Federal Claims ruled Dell did not prove Minburn Technology Group's claim lacked merit. The contract involves cloud subscriptions and Microsoft products. Judge Loren A. Smith denied Dell's motion to dismiss.